• Discounts and special offers
  • Subscriber-only articles and interviews
  • Breaking news and trending topics

Already a subscriber?

By signing up, you accept Moneywise's Terms of Use, Subscription Agreement, and Privacy Policy.

Not interested ?

D.R. Horton

Homebuilders recently got a vote of confidence from Buffett himself after the Oracle of Omaha added a few homebuilder stocks to his portfolio, including D.R. Horton (DHI). He seems to be betting on a boom in home construction, which could be justified by the ongoing shortage of housing across North America.

According to a March report from Realtor.com, the U.S. housing market is short 6.5 million single-family units due to a deade of under-building. This gap could begin to close if more households opt for multi-family units and more construction gets underway. That’s where companies like D.R. Horton step in.

Meanwhile, the stock is undervalued—trading at around 10 times earnings per share. Consider placing this cheap, Buffett-backed stock on your radar for a long-term investment.

Elevate Your Investments with Moby

Gain a competitive edge with Moby's expert investing insights. Our data-driven analysis and personalized recommendations empower you to make smarter investment decisions. Enhance your portfolio and stay ahead of market trends. Start your journey to financial success today at Moby.

Get Started

Eli Lilly

Pharmaceutical giants are usually good long-term bets. That’s because once a drug or treatment from their pipeline is approved, it can generate revenue and profits for decades. Eli Lilly (LLY) recently received approval for Mounjaro, a drug it intends to deploy in the weight loss market. Effectively, the company has entered into competition with Ozempic, which is one of Danish drugmaker Novo Nordisk’s products.

This market could be worth $71 billion by 2032, according to a report by J.P. Morgan stock analyst Richard Vosser cited by Fierce Pharma, with Eli Lilly capturing a significant chunk of it.

That’s just one drug in a broad portfolio. Eli Lilly already has a track record of steady growth and investment in research and development. As a result, the stock has delivered a total return of more than 1,000% over the past 10 years.

An impressive history and promising future should put this stock on your long-term watch list.

Microsoft

Savvy investments and early moves have put Microsoft (MSFT) at the forefront of developments in artificial intelligence. And the company already has a significant stake in the most promising startup in this field: OpenAI.

OpenAI’s products, like ChatGPT, have already been integrated into Microsoft’s software suite. The tech giant also recently secured a nonvoting seat on the startup’s board.

Microsoft recently expanded this advantage by building its own custom AI chip.

It’s too early to say what impact AI will have on our economy in the future. But it seems increasingly likely that Microsoft will play a pivotal role in this future. That’s why long-term investors may want to consider adding this stock to their “forever” watch list.

Sponsored

This 2 Minute Move Could Knock $500/Year off Your Car Insurance in 2024

Saving money on car insurance with BestMoney is a simple way to reduce your expenses. You’ll often get the same, or even better, insurance for less than what you’re paying right now.

There’s no reason not to at least try this free service. Check out BestMoney today, and take a turn in the right direction.

Vishesh Raisinghani Freelance Writer

Vishesh Raisinghani is a freelance contributor at MoneyWise. He has been writing about financial markets and economics since 2014 - having covered family offices, private equity, real estate, cryptocurrencies, and tech stocks over that period. His work has appeared in Seeking Alpha, Motley Fool Canada, Motley Fool UK, Mergers & Acquisitions, National Post, Financial Post, and Yahoo Canada.

Disclaimer

The content provided on Moneywise is information to help users become financially literate. It is neither tax nor legal advice, is not intended to be relied upon as a forecast, research or investment advice, and is not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. Tax, investment and all other decisions should be made, as appropriate, only with guidance from a qualified professional. We make no representation or warranty of any kind, either express or implied, with respect to the data provided, the timeliness thereof, the results to be obtained by the use thereof or any other matter.